Join
Live feed
·
PRReleasevia Quantisnow
ADC Therapeutics SA logo

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
ADCT· ADC Therapeutics SA
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADCT (ADC Therapeutics SA) and more on Quantisnow.